We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
News

Sartorius Acquires Cellca

Rectangle Image
News

Sartorius Acquires Cellca

Read time:
 

Cellca’s major customers are biopharmaceutical companies as well as biosimilar firms that do not or only partly conduct their process development in their in-house facilities. Through this acquisition, Sartorius Stedim Biotech is further expanding its service offering for process development, according to Reinhard Vogt, a member of the SSB executive committee for marketing and sales, who added that SSB has already strengthened this segment by its two recent acquisitions of BioOutsource and TAP Biosystems.

“Together with our single-use products, media and testing services, we are creating an attractive package, above all for young biopharmaceutical companies that need robust processes for the manufacture of their biologics," he explained

Founded in 2005, Cellca has a staff of 30 employees and generated sales revenue of approximately €6 million (about $6.65 million) in 2014.

Advertisement